SBC
SBC Medical Group Holdings Incorporated
Consulting Services
Market Cap$330M
5Y Perf.-67.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SBC vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
SKIN
The Beauty Health Company
Household & Personal Products
Market Cap$121M
5Y Perf.-92.1%
SBC vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SBC | SKIN |
|---|---|---|
| Industry | Consulting Services | Household & Personal Products |
| Market Cap | $330M | $121M |
| Revenue (TTM) | $178M | $301M |
| Net Income (TTM) | $43M | $-10M |
| Gross Margin | 73.7% | 65.3% |
| Operating Margin | 33.3% | -6.9% |
| Forward P/E | 7.1x | — |
| Total Debt | $12M | $379M |
| Cash & Equiv. | $125M | $233M |
SBC vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SBC
SKIN
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| SBC Medical Group H… (SBC) | 100 | 32.1 | -67.9% |
| The Beauty Health C… (SKIN) | 100 | 7.9 | -92.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBC vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SBC leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. The Beauty Health Company is the stronger pick specifically for valuation and capital efficiency. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SBC
SBC Medical Group Holdings Incorporated
The Income Pick
SBC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.76
- Rev growth 6.1%, EPS growth 15.5%
- -67.7% 10Y total return vs SKIN's -91.4%
Best for: income & stability and growth exposure
SKIN
The Beauty Health Company
The Value Play
SKIN is the clearest fit if your priority is value.
- Better valuation composite
Best for: value
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SBC | 6.1% revenue growth vs SKIN's -10.0% |
| Value | SKIN | Better valuation composite |
| Quality / Margins | SBC | 24.3% margin vs SKIN's -3.2% |
| Stability / Safety | SBC | Beta 0.76 vs SKIN's 2.00, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SBC | +3.2% vs SKIN's -11.2% |
| Efficiency (ROA) | SBC | 13.5% ROA vs SKIN's -1.7%, ROIC 72.3% vs -6.8% |
SBC vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
SBC vs SKIN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSBCLAGGINGSKIN
SKINThe Beauty Health Com…
1leads
SBCSBC Medical Group Hol…
4leads
6 Total Categories
CATEGORYLEADERvs SKINMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SBC4/6
Valuation MetricsMultiples, price ratios, and targets
SKIN3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SBC8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SBC6/6
Risk & VolatilityBeta, volatility, and downside exposure
SBC2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SBC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SKIN is the larger business by revenue, generating $301M annually — 1.7x SBC's $178M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to SKIN's -3.2%. On growth, SKIN holds the edge at -1.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| RevenueTrailing 12 months | $178M | $301M |
| EBITDAEarnings before interest/tax | $62M | $5M |
| Net IncomeAfter-tax profit | $43M | -$10M |
| Free Cash FlowCash after capex | -$37M | $36M |
| Gross MarginGross profit ÷ Revenue | +73.7% | +65.3% |
| Operating MarginEBIT ÷ Revenue | +33.3% | -6.9% |
| Net MarginNet income ÷ Revenue | +24.3% | -3.2% |
| FCF MarginFCF ÷ Revenue | -20.5% | +12.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.3% | -1.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.2% | +23.4% |
SBC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
SKIN leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, SBC's 2.9x EV/EBITDA is more attractive than SKIN's 7412.9x.
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| Market CapShares × price | $330M | $121M |
| Enterprise ValueMkt cap + debt − cash | $217M | $267M |
| Trailing P/EPrice ÷ TTM EPS | 6.67x | -5.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.09x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 2.93x | 7412.86x |
| Price / SalesMarket cap ÷ Revenue | 1.61x | 0.40x |
| Price / BookPrice ÷ Book value/share | 1.59x | 2.07x |
| Price / FCFMarket cap ÷ FCF | 19.23x | 3.25x |
SKIN leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
SBC leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-15 for SKIN. SBC carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x.
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| ROE (TTM)Return on equity | +17.5% | -15.4% |
| ROA (TTM)Return on assets | +13.5% | -1.7% |
| ROICReturn on invested capital | +72.3% | -6.8% |
| ROCEReturn on capital employed | +37.9% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 6.20x |
| Net DebtTotal debt minus cash | -$113M | $146M |
| Cash & Equiv.Liquid assets | $125M | $233M |
| Total DebtShort + long-term debt | $12M | $379M |
| Interest CoverageEBIT ÷ Interest expense | 596.05x | 0.62x |
SBC leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SBC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SBC five years ago would be worth $3,233 today (with dividends reinvested), compared to $726 for SKIN. Over the past 12 months, SBC leads with a +3.2% total return vs SKIN's -11.2%. The 3-year compound annual growth rate (CAGR) favors SBC at -32.2% vs SKIN's -56.0% — a key indicator of consistent wealth creation.
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| YTD ReturnYear-to-date | -25.6% | -33.4% |
| 1-Year ReturnPast 12 months | +3.2% | -11.2% |
| 3-Year ReturnCumulative with dividends | -68.8% | -91.5% |
| 5-Year ReturnCumulative with dividends | -67.7% | -92.7% |
| 10-Year ReturnCumulative with dividends | -67.7% | -91.4% |
| CAGR (3Y)Annualised 3-year return | -32.2% | -56.0% |
SBC leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SBC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SBC is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SBC currently trades 56.0% from its 52-week high vs SKIN's 34.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 2.00x |
| 52-Week HighHighest price in past year | $5.75 | $2.69 |
| 52-Week LowLowest price in past year | $2.97 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +56.0% | +34.7% |
| RSI (14)Momentum oscillator 0–100 | 28.7 | 48.3 |
| Avg Volume (50D)Average daily shares traded | 87K | 718K |
SBC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SBC as "Buy" and SKIN as "Hold". Consensus price targets imply 179.5% upside for SBC (target: $9) vs 39.4% for SKIN (target: $1).
| Metric | SBCSBC Medical Group… | SKINThe Beauty Health… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $9.00 | $1.30 |
| # AnalystsCovering analysts | 1 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SBC leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SKIN leads in 1 (Valuation Metrics).
Best OverallSBC Medical Group Holdings … (SBC)Leads 4 of 6 categories
Loading custom metrics...
SBC vs SKIN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SBC or SKIN a better buy right now?
For growth investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger pick with 6.
1% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SBC or SKIN?
Over the past 5 years, SBC Medical Group Holdings Incorporated (SBC) delivered a total return of -67.
7%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: SBC returned -67. 7% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SBC or SKIN?
By beta (market sensitivity over 5 years), SBC Medical Group Holdings Incorporated (SBC) is the lower-risk stock at 0.
76β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 163% more volatile than SBC relative to the S&P 500. On balance sheet safety, SBC Medical Group Holdings Incorporated (SBC) carries a lower debt/equity ratio of 6% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — SBC or SKIN?
By revenue growth (latest reported year), SBC Medical Group Holdings Incorporated (SBC) is pulling ahead at 6.
1% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to 15. 5% for SBC Medical Group Holdings Incorporated. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SBC or SKIN?
SBC Medical Group Holdings Incorporated (SBC) is the more profitable company, earning 22.
7% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — SBC leads at 76. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SBC or SKIN more undervalued right now?
Analyst consensus price targets imply the most upside for SBC: 179.
5% to $9. 00.
07Which pays a better dividend — SBC or SKIN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SBC or SKIN better for a retirement portfolio?
For long-horizon retirement investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
76)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SBC: -67. 7%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SBC and SKIN?
These companies operate in different sectors (SBC (Industrials) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SBC is a small-cap deep-value stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SBC: -18.3% · SKIN: -1.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.